Home Online Features U.S. FDA Granted Priority Review to Dizal's Sunvozertinib New Drug Application
U.S. FDA Granted Priority Review to Dizal’s Sunvozertinib New Drug Application
Hand-out
Press Releases
Dizal Pharmaceutical  
January 7, 2025

U.S. FDA Granted Priority Review to Dizal’s Sunvozertinib New Drug Application

If approved, Sunvozertinib as a single oral drug would offer a convenient and safe treatment option with superior efficacy for NSCLC patients with EGFR exon20insSunvozertinib's NDA was submitted based on

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social